Additionally, the renal benefits of GLP-1 have been described in patients with obesity, with or without T2DM, through studies such as the AMPLITUDE-O trial (Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes), which demonstrated a reduction in albuminuria and less deterioration of renal function in the efpeglenatide group [77]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.